Money
Filter News
Found 84,825 articles
-
Intra-Cellular Therapies Prices Public Offering of Common Stock - April 18, 2024
4/18/2024
Intra-Cellular Therapies, Inc. announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share.
-
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
4/18/2024
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its full-year 2023 financial results for the period ended December 31, 2023 and provided a corporate update.
-
As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis.
-
Inflammatory disease–focused Mirador Therapeutics landed the largest early-stage VC investment in biopharma last quarter, as more companies are securing $150 million or more.
-
The Menlo Park, Calif.-based venture capital firm has raised more than $1 billion since last year, with this latest injection of capital going to its biopharma investment funds.
-
On the heels of a Phase IIb win, Arrowhead Pharmaceuticals’ plozasiran could fulfill a critical unmet need in dyslipidemia treatment bringing in $707 million in sales by 2032, according to data analytics firm GlobalData.
-
BAP Pharma Announces Grand Opening Ceremony for New US Headquarters in Somerset, NJ
4/17/2024
BAP Pharma will welcome guests and dignitaries to the Grand Opening Ceremony of its new headquarters on Randolph Road with a formal ribbon cutting ceremony, speeches, and exclusive tours of the new facility.
-
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
4/17/2024
Vanda Pharmaceuticals Inc. announced that its Board of Directors has adopted a limited duration stockholder rights plan to protect stockholder interests and maximize value for all stockholders.
-
Asieris Pharmaceuticals Unveils 2023 Annual Report, Core Product APL-1702 Succeeds in Global Phase III Clinical Trials, APL-1706 obtains NDA acceptance domestically, Specialty Commercial Team Generates Sustained Revenue Streams
4/17/2024
Asieris Pharmaceuticals released its 2023 Annual Report, revealing impressive outcomes achieved through its specialty pharma strategy, which has facilitated rapid progress in clinical development, early research, and commercialization.
-
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
4/17/2024
NANOBIOTIX announced that it will report its financial and operational results for the fourth quarter and full year ended December 31, 2023, on Wednesday, April 24, 2024, after the close of the US market.
-
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock - April 17, 2024
4/17/2024
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it intends to offer to sell shares of its common stock in an underwritten public offering.
-
Biohaven Announces Proposed Public Offering of Common Shares - April 17, 2024
4/17/2024
Biohaven Ltd. announced that it has commenced an underwritten public offering of $200 million of its common shares.
-
Xeno Biosciences Announces New CEO and Financing - April 17, 2024
4/17/2024
Xeno Biosciences Inc. announced a change in executive leadership as of September 2023, and the completion of an additional financing round in February of 2024.
-
Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics
4/17/2024
Sound Bioventures announced a new investment in Theolytics, a UK biotechnology company developing next-generation oncolytic viral therapies.
-
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
4/17/2024
Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, announced it has successfully closed its latest financing round, raising a total of £19M with the addition of Sound Bioventures as a new investor.
-
Q1 2024 Revenue and Business Update
4/17/2024
Telix Pharmaceuticals Limited provides an update on its revenue and operational performance for the quarter ended 31 March 2024.
-
SCG Cell Therapy and A*STAR Launch Joint Labs With Collaboration Nearing S$30 Million to Advance iPSC Technology Towards Scalable GMP Manufacturing of Cellular Immunotherapies
4/17/2024
SCG Cell Therapy and the Agency for Science, Technology and Research announced the launch joint laboratories for cellular immunotherapies.
-
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
4/17/2024
TScan Therapeutics, Inc. announced the pricing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of the market price of $7.1300 per share, which was equal to the closing price of its voting common stock on the Nasdaq Global Market on April 16, 2024.
-
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
4/17/2024
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the year ended December 31, 2023.
-
Awakn Life Sciences Announces Closing of Tranche of Private Placement
4/17/2024
Toronto, Ontario--(Newsfile Corp. - April 17, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with...